Surveillance of SARS-CoV-2 variants in Argentina: detection of Alpha, Gamma, Lambda, Epsilon and Zeta in locally transmitted and imported cases
Abstract
Molecular surveillance of SARS-CoV-2 variants was performed on a total of 2,406 samples from the capital city and nine provinces of Argentina, during 30 epidemiological weeks (EW) that covered the end of the first wave and the beginning of the ongoing second wave of the COVID-19 pandemic in the country (EW 44/2020 to EW 20/2021). The surveillance strategy was mainly based on Sanger sequencing of a Spike coding region that allows the simultaneous identification of signature mutations associated with worldwide circulating variants. In addition, whole SARS-CoV-2 genome sequences were obtained from 456 samples. The main variants found were Gamma, Lambda and Alpha, and to a lesser extent, Zeta and Epsilon. Whereas Gamma dominated in different regions of the country, both Gamma and Lambda prevailed in the most populated area, the metropolitan region of Buenos Aires (MABA), although showing a heterogeneous distribution along this region. This cost-effective surveillance protocol allowed for a rapid response in a limited access to resources scenario, added information on the expansion of the Lambda variant in South America and contributed to the implementation of public health measures to control the disease spread in Argentina.
- SARS-CoV-2
- variants
- South America
- Argentina
- surveillance
- Spike sequence
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Proyecto IP COVID-19 N 08 and Focem COF 03/11 Covid-19.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All relevant ethical guidelines have been appropriately followed. The study was approved by the Ethics Committee of the Hospital de Ninos Ricardo Gutierrez, CABA, Argentina.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
The sequences obtained in this study can be found in the online repository GISAID.
Subject Area
- Addiction Medicine (373)
- Allergy and Immunology (690)
- Anesthesia (184)
- Cardiovascular Medicine (2760)
- Dermatology (236)
- Emergency Medicine (414)
- Epidemiology (12413)
- Forensic Medicine (10)
- Gastroenterology (784)
- Genetic and Genomic Medicine (4272)
- Geriatric Medicine (396)
- Health Economics (702)
- Health Informatics (2761)
- Health Policy (1021)
- Hematology (370)
- HIV/AIDS (880)
- Medical Education (404)
- Medical Ethics (112)
- Nephrology (454)
- Neurology (4054)
- Nursing (218)
- Nutrition (600)
- Oncology (2134)
- Ophthalmology (607)
- Orthopedics (251)
- Otolaryngology (313)
- Pain Medicine (256)
- Palliative Medicine (77)
- Pathology (479)
- Pediatrics (1150)
- Primary Care Research (470)
- Public and Global Health (6663)
- Radiology and Imaging (1453)
- Respiratory Medicine (886)
- Rheumatology (422)
- Sports Medicine (353)
- Surgery (465)
- Toxicology (57)
- Transplantation (192)
- Urology (171)